Aralez Pharmaceuticals Inc.
ARLZ
ARLZ was delisted on the 20th of August, 2018.
63 hedge funds and large institutions have $17.1M invested in Aralez Pharmaceuticals Inc. in 2017 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 16 increasing their positions, 17 reducing their positions, and 7 closing their positions.
57% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 7
7% more funds holding
Funds holding: 59 → 63 (+4)
6% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 17
1.56% less ownership
Funds ownership: 19.43% → 17.87% (-1.6%)
42% less capital invested
Capital invested by funds: $29.6M → $17.1M (-$12.5M)
64% less call options, than puts
Call options by funds: $63K | Put options by funds: $175K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$679K |
| 2 |
Goldman Sachs
New York
|
+$264K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$156K |
| 4 |
D.E. Shaw & Co
New York
|
+$136K |
| 5 |
Millennium Management
New York
|
+$108K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.28M |
| 2 |
PCM
PAR Capital Management
Boston,
Massachusetts
|
-$751K |
| 3 |
CIM
Contrarius Investment Management
St. Helier,
Jersey
|
-$495K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$451K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$123K |
ARLZ Hedge Fund Activity: Q4 2017 in Review
63 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Aralez Pharmaceuticals Inc. (ARLZ) for Q4 2017, worth a combined $17.1M — down 42% from $29.6M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new ARLZ positions and 7 closed out — a net gain of 4 holders — while 16 added to existing stakes and 17 trimmed.
The largest buyer was Wells Fargo, adding an estimated $679K. The largest seller was BlackRock, exiting entirely with an estimated $2.28M sold.
- 63 institutional investors held Aralez Pharmaceuticals Inc. (ARLZ) as of Q4 2017, up from 59 in Q3 2017.
- Funds reported $17.1M of Aralez Pharmaceuticals Inc. stock for Q4 2017, down 42% quarter-over-quarter.
- 11 funds opened new Aralez Pharmaceuticals Inc. positions in Q4 2017 and 7 closed out, a net change of +4 holders.
- The largest Aralez Pharmaceuticals Inc. buyer in Q4 2017 was Wells Fargo, an estimated $679K added.
- The largest Aralez Pharmaceuticals Inc. seller in Q4 2017 was BlackRock, an estimated $2.28M sold.
Based on aggregated 13F filings for Q4 2017.